AngioDynamics (FRA:UG2) Beneish M-Score: -2.94 (As of Jun. 24, 2026)


FRA:UG2 AngioDynamics Inc FRA:UG2
62 GF Score
Price €10.80
GF Value €7.27
! 7 Warning Signs
View Full Analysis

What is AngioDynamics Beneish M-Score?

AngioDynamics FRA:UG2 -0.92% 62 Beneish M-Score is -2.94 as of Jun. 24, 2026. GuruFocus rates FRA:UG2 with a GF Score™ of 62/100 and a GF Value™ of €7.27. The stock has 7 warning signs investors should review. Among 765 Medical Devices & Instruments companies, AngioDynamics ranks better than 75.03% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.94 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for AngioDynamics's Beneish M-Score or its related term are showing as below:

FRA:UG2' s Beneish M-Score Range Over the Past 10 Years
Min: -3.53   Med: -2.7   Max: -1.98
Current: -2.94

During the past 13 years, the highest Beneish M-Score of AngioDynamics was -1.98. The lowest was -3.53. And the median was -2.70.


AngioDynamics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for AngioDynamics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioDynamics Beneish M-Score Chart

AngioDynamics Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.61 -2.21 -2.86 -2.76 -2.84

AngioDynamics Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.55 -2.84 -2.70 -2.68 -2.94

FRA:UG2 vs OSUR, UTMD, SMTI: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, AngioDynamics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Beneish M-Score falls into.


FRA:UG2
62GF Score
AngioDynamics Inc FRA:UG2
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AngioDynamics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of AngioDynamics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7999+0.528 * 1.0012+0.404 * 1.032+0.892 * 1.0249+0.115 * 0.9912
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9584+4.679 * -0.100606-0.327 * 0.9277
=-3.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb26) TTM:Last Year (Feb25) TTM:
Total Receivables was €38.5 Mil.
Revenue was 66.346 + 68.71 + 65.036 + 71.1 = €271.2 Mil.
Gross Profit was 35.091 + 38.737 + 35.955 + 37.447 = €147.2 Mil.
Total Current Assets was €131.6 Mil.
Total Assets was €220.5 Mil.
Property, Plant and Equipment(Net PPE) was €24.7 Mil.
Depreciation, Depletion and Amortization(DDA) was €20.0 Mil.
Selling, General, & Admin. Expense(SGA) was €131.6 Mil.
Total Current Liabilities was €55.9 Mil.
Long-Term Debt & Capital Lease Obligation was €0.0 Mil.
Net Income was -6.839 + -5.493 + -9.366 + -5.366 = €-27.1 Mil.
Non Operating Income was -1.316 + -3.255 + -2.522 + -2.2 = €-9.3 Mil.
Cash Flow from Operations was -2.631 + 4.032 + -13.67 + 16.685 = €4.4 Mil.
Total Receivables was €47.0 Mil.
Revenue was 69.124 + 68.62 + 61.214 + 65.656 = €264.6 Mil.
Gross Profit was 37.303 + 37.591 + 33.309 + 35.626 = €143.8 Mil.
Total Current Assets was €165.4 Mil.
Total Assets was €274.0 Mil.
Property, Plant and Equipment(Net PPE) was €31.2 Mil.
Depreciation, Depletion and Amortization(DDA) was €25.0 Mil.
Selling, General, & Admin. Expense(SGA) was €134.0 Mil.
Total Current Liabilities was €74.9 Mil.
Long-Term Debt & Capital Lease Obligation was €0.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(38.537 / 271.192) / (47.009 / 264.614)
=0.142102 / 0.177651
=0.7999

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(143.829 / 264.614) / (147.23 / 271.192)
=0.543543 / 0.542899
=1.0012

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (131.597 + 24.654) / 220.534) / (1 - (165.382 + 31.229) / 273.998)
=0.291488 / 0.282436
=1.032

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=271.192 / 264.614
=1.0249

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(24.991 / (24.991 + 31.229)) / (20.046 / (20.046 + 24.654))
=0.444522 / 0.448456
=0.9912

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(131.643 / 271.192) / (134.02 / 264.614)
=0.485424 / 0.506474
=0.9584

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 55.892) / 220.534) / ((0 + 74.852) / 273.998)
=0.253439 / 0.273184
=0.9277

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-27.064 - -9.293 - 4.416) / 220.534
=-0.100606

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

AngioDynamics has a M-score of -3.07 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.94 mean?
AngioDynamics (FRA:UG2) has a Beneish M-Score of -2.94 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on AngioDynamics and its competitors. According to the industry distribution chart, AngioDynamics ranks #191 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 25%.
Is AngioDynamics' Beneish M-Score too high?
AngioDynamics' current Beneish M-Score is -2.94. Based on the distribution chart, AngioDynamics ranks #191 out of 765 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, AngioDynamics has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does AngioDynamics' Beneish M-Score compare to OSUR and UTMD?
According to the Medical Devices & Instruments industry distribution chart, AngioDynamics ranks #191 out of 765 companies for Beneish M-Score. This places AngioDynamics in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on AngioDynamics and its competitors. AngioDynamics's current Beneish M-Score is -2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AngioDynamics stock overvalued right now?
AngioDynamics (FRA:UG2) has a current Beneish M-Score of -2.94. The stock's GF Value™ is €7.27, compared to a current price of €10.80 — trading 48.6% above its estimated fair value. The current Beneish M-Score is -2.94. AngioDynamics' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For AngioDynamics (FRA:UG2), the current Beneish M-Score is -2.94 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AngioDynamics (FRA:UG2) Overvalued in 2026?

Based on GuruFocus' analysis, AngioDynamics stock appears to be overvalued. The current stock price of €10.80 is trading 48.6% above its estimated GF Value™ of €7.27.

Key valuation signals for FRA:UG2:

  • Beneish M-Score: -2.94
  • GF Value™: €7.27 vs. price of €10.80 (48.6% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the FRA:UG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AngioDynamics Business Description

Other Exchanges ANGO:USA
Address 14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
62GF Score

Get the complete analysis for FRA:UG2

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.80
Price
€7.27
GF Value